|Day Low/High||55.06 / 58.39|
|52 Wk Low/High||50.71 / 68.12|
Stock trading is choppy on Friday afternoon after federal investigators reopen a case into Democratic presidential candidate Hillary Clinton's email server.
Shares of AbbVie were lower Friday after posting disappointing third-quarter revenue.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
Stocks fluctuate on Friday morning after third-quarter growth in the U.S. economy picks up speed.
AbbVie (ABBV) posted mixed results for the 2016 third quarter this morning.
Stock futures move higher on Friday morning after third-quarter growth in the U.S. economy picks up speed and Alphabet posts better-than-expected earnings.
AbbVie (ABBV) is slated to post 2016 third quarter results before the market open on Friday.
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Here's your 'silver linings playbook' for what promises to be a nerve-wracking week of unpredictable politics, mixed corporate earnings and volatile energy prices.
- Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis
In the near term Abbvie bulls should take a more positive view of the stock.
With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.
We continue to believe the company is attractive to buy at 11.2x expected 2017 earnings of $5.64 a share.
Keep an eye on Eaton Vance and these 6 notable dividend must-own dates.
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
- Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)
Stock losses accelerate on Thursday as Deutsche Bank and Wells Fargo drag on the financials sector.
- New site to expand the company's global operations for small molecule and biologics manufacturing
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
- New Phase 2 open-label extension data to be presented on investigational biologic compound risankizumab, an anti-IL-23 monoclonal antibody, currently under investigation for moderate to severe chronic plaque psoriasis